You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2024

Investigational Drug Information for Verinurad


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Verinurad?

Verinurad is an investigational drug.

There have been 9 clinical trials for Verinurad. The most recent clinical trial was a Phase 2 trial, which was initiated on May 18th 2017.

The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Hyperuricemia. The leading clinical trial sponsors are AstraZeneca, Parexel, and Analytical Laboratory (Pharmacokinetic Sample Analysis): USA.

There are twelve US patents protecting this investigational drug and one hundred and eighty international patents.

Recent Clinical Trials for Verinurad
TitleSponsorPhase
A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and AllopurinolParexelPhase 1
A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and AllopurinolAstraZenecaPhase 1
Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy VolunteersParexelPhase 1

See all Verinurad clinical trials

Clinical Trial Summary for Verinurad

Top disease conditions for Verinurad
Top clinical trial sponsors for Verinurad

See all Verinurad clinical trials

US Patents for Verinurad

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Verinurad ⤷  Sign Up 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same ARDEA BIOSCIENCES, INC. (San Diego, CA) ⤷  Sign Up
Verinurad ⤷  Sign Up Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN) ⤷  Sign Up
Verinurad ⤷  Sign Up Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN) ⤷  Sign Up
Verinurad ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Verinurad ⤷  Sign Up URAT1 inhibitor Nippon Chemiphar Co., Ltd. (Tokyo, JP) J-Pharma Co., Ltd. (Kanagawa, JP) DeThree Res. Lab. Inc. (Ibaraki, JP) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Verinurad

Drugname Country Document Number Estimated Expiration Related US Patent
Verinurad Australia AU2012332154 2031-11-03 ⤷  Sign Up
Verinurad Brazil BR112014010495 2031-11-03 ⤷  Sign Up
Verinurad Canada CA2852490 2031-11-03 ⤷  Sign Up
Verinurad China CN104023723 2031-11-03 ⤷  Sign Up
Verinurad China CN106963761 2031-11-03 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.